vs
艾伯维（ABBV）与LG化学（CHE）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是LG化学的39.6倍（$16.6B vs $420.0M）。LG化学净利率更高（15.8% vs 10.9%，领先4.9%）。艾伯维同比增速更快（10.0% vs 3.1%）。过去两年艾伯维的营收复合增速更高（16.2% vs 5.9%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
LG化学是韩国最大的化工企业，总部位于韩国首尔，2021年按销售额统计为全球第九大化工企业。其前身为生产化妆品的乐喜化学工业株式会社，目前已全面转型为仅面向企业客户的B2B经营模式。
ABBV vs CHE — 直观对比
营收规模更大
ABBV
是对方的39.6倍
$420.0M
营收增速更快
ABBV
高出6.9%
3.1%
净利率更高
CHE
高出4.9%
10.9%
两年增速更快
ABBV
近两年复合增速
5.9%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $420.0M |
| 净利润 | $1.8B | $66.3M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 20.1% |
| 净利率 | 10.9% | 15.8% |
| 营收同比 | 10.0% | 3.1% |
| 净利润同比 | 8354.5% | -7.6% |
| 每股收益（稀释后） | $1.02 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVCHE
| Q1 26 | — | $420.0M | ||
| Q4 25 | $16.6B | $639.3M | ||
| Q3 25 | $15.8B | $624.9M | ||
| Q2 25 | $15.4B | $618.8M | ||
| Q1 25 | $13.3B | $646.9M | ||
| Q4 24 | $15.1B | $411.0M | ||
| Q3 24 | $14.5B | $391.4M | ||
| Q2 24 | $14.5B | $374.6M |
净利润ABBVCHE
| Q1 26 | — | $66.3M | ||
| Q4 25 | $1.8B | $76.8M | ||
| Q3 25 | $186.0M | $64.2M | ||
| Q2 25 | $938.0M | $52.5M | ||
| Q1 25 | $1.3B | $71.8M | ||
| Q4 24 | $-22.0M | $90.3M | ||
| Q3 24 | $1.6B | $75.8M | ||
| Q2 24 | $1.4B | $70.9M |
毛利率ABBVCHE
| Q1 26 | — | — | ||
| Q4 25 | 72.6% | 35.2% | ||
| Q3 25 | 66.4% | 31.5% | ||
| Q2 25 | 71.8% | 29.8% | ||
| Q1 25 | 70.0% | 33.5% | ||
| Q4 24 | 70.9% | 1.2% | ||
| Q3 24 | 70.9% | -1.2% | ||
| Q2 24 | 70.9% | -4.1% |
营业利润率ABBVCHE
| Q1 26 | — | 20.1% | ||
| Q4 25 | 27.3% | 15.7% | ||
| Q3 25 | 12.1% | 12.0% | ||
| Q2 25 | 31.7% | 11.0% | ||
| Q1 25 | 28.0% | 14.6% | ||
| Q4 24 | -9.9% | 27.7% | ||
| Q3 24 | 26.5% | 23.5% | ||
| Q2 24 | 27.6% | 23.5% |
净利率ABBVCHE
| Q1 26 | — | 15.8% | ||
| Q4 25 | 10.9% | 12.0% | ||
| Q3 25 | 1.2% | 10.3% | ||
| Q2 25 | 6.1% | 8.5% | ||
| Q1 25 | 9.6% | 11.1% | ||
| Q4 24 | -0.1% | 22.0% | ||
| Q3 24 | 10.8% | 19.4% | ||
| Q2 24 | 9.5% | 18.9% |
每股收益（稀释后）ABBVCHE
| Q1 26 | — | — | ||
| Q4 25 | $1.02 | $5.45 | ||
| Q3 25 | $0.10 | $4.46 | ||
| Q2 25 | $0.52 | $3.57 | ||
| Q1 25 | $0.72 | $4.86 | ||
| Q4 24 | $-0.03 | $6.00 | ||
| Q3 24 | $0.88 | $5.00 | ||
| Q2 24 | $0.77 | $4.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $16.9M |
| 总债务越低越好 | $58.9B | $91.2M |
| 股东权益账面价值 | $-3.3B | $848.0M |
| 总资产 | $134.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资ABBVCHE
| Q1 26 | — | $16.9M | ||
| Q4 25 | $5.3B | $74.5M | ||
| Q3 25 | $5.7B | $129.8M | ||
| Q2 25 | $6.5B | $249.9M | ||
| Q1 25 | $5.2B | $173.9M | ||
| Q4 24 | $5.6B | $178.3M | ||
| Q3 24 | $7.3B | $238.5M | ||
| Q2 24 | $13.2B | $222.9M |
总债务ABBVCHE
| Q1 26 | — | $91.2M | ||
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — |
股东权益ABBVCHE
| Q1 26 | — | $848.0M | ||
| Q4 25 | $-3.3B | $979.4M | ||
| Q3 25 | $-2.6B | $1.1B | ||
| Q2 25 | $-183.0M | $1.2B | ||
| Q1 25 | $1.4B | $1.2B | ||
| Q4 24 | $3.3B | $1.1B | ||
| Q3 24 | $6.0B | $1.2B | ||
| Q2 24 | $6.8B | $1.2B |
总资产ABBVCHE
| Q1 26 | — | $1.5B | ||
| Q4 25 | $134.0B | $1.5B | ||
| Q3 25 | $133.9B | $1.6B | ||
| Q2 25 | $137.2B | $1.7B | ||
| Q1 25 | $136.2B | $1.7B | ||
| Q4 24 | $135.2B | $1.7B | ||
| Q3 24 | $143.4B | $1.8B | ||
| Q2 24 | $141.9B | $1.7B |
负债/权益比ABBVCHE
| Q1 26 | — | 0.11× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $88.2M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | 4.1% |
| 现金转化率经营现金流/净利润 | 2.87× | 1.33× |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVCHE
| Q1 26 | — | $88.2M | ||
| Q4 25 | $5.2B | $133.5M | ||
| Q3 25 | $7.0B | $83.4M | ||
| Q2 25 | $5.2B | $138.6M | ||
| Q1 25 | $1.6B | $32.7M | ||
| Q4 24 | $7.0B | $164.9M | ||
| Q3 24 | $5.4B | $90.5M | ||
| Q2 24 | $2.3B | $77.5M |
自由现金流ABBVCHE
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $117.2M | ||
| Q3 25 | $6.6B | $66.0M | ||
| Q2 25 | $4.9B | $122.8M | ||
| Q1 25 | $1.4B | $19.5M | ||
| Q4 24 | $6.8B | $152.2M | ||
| Q3 24 | $5.2B | $77.0M | ||
| Q2 24 | $2.0B | $66.5M |
自由现金流率ABBVCHE
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | 18.3% | ||
| Q3 25 | 42.1% | 10.6% | ||
| Q2 25 | 31.7% | 19.8% | ||
| Q1 25 | 10.5% | 3.0% | ||
| Q4 24 | 44.7% | 37.0% | ||
| Q3 24 | 35.9% | 19.7% | ||
| Q2 24 | 14.0% | 17.7% |
资本支出强度ABBVCHE
| Q1 26 | — | 4.1% | ||
| Q4 25 | 2.0% | 2.6% | ||
| Q3 25 | 2.4% | 2.8% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.8% | 2.1% | ||
| Q4 24 | 1.9% | 3.1% | ||
| Q3 24 | 1.7% | 3.5% | ||
| Q2 24 | 1.7% | 3.0% |
现金转化率ABBVCHE
| Q1 26 | — | 1.33× | ||
| Q4 25 | 2.87× | 1.74× | ||
| Q3 25 | 37.76× | 1.30× | ||
| Q2 25 | 5.49× | 2.64× | ||
| Q1 25 | 1.27× | 0.46× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | 3.49× | 1.19× | ||
| Q2 24 | 1.66× | 1.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
CHE
| Homecare | $371.1M | 88% |
| Inpatient | $35.9M | 9% |
| Other | $13.0M | 3% |
